Sequential recovery masks YoY miss; long capex cycle ahead

Contrast media declined QoQ; YoY revenue -17.4%; transit delays cited for Q1 shortfall

Q1 saw sharp PI/API recovery; management reports strong order book and visibility for 3–4 quarters

YoY revenue -17.4%, PAT -14.2%; quarter marked as 'investment phase' continuation, not growth phase start

Delivered 24.9% QoQ growth; matches guidance

Management cited 'improving visibility' and 'confidence in medium and long-term growth trajectory' but avoided numeric FY27 guidance. Contrast with prior call's 'double-digit growth in contrast media.'

Current EBITDA margin 33.5%. Raw material price pass-through hedged and delayed ('will evaluate case-by-case'). No commitment to margin expansion or floor.

FY27 spend for Hyderabad R&D and Mahad finish. Vizag commercialization end FY29–FY30. Asset payoff FY31–FY32. Execution risk on large capex and new facilities unproven.

PI/API (Bempedoic/cardiovascular molecule) appears to be primary growth driver and order-book anchor. Contrast media decline and timing volatility suggests core business lacks diversification. Reliance on few large innovator accounts.

Contrast media revenue recognized only when product reaches customer location per contract terms. Q1 goods in transit ₹30 Cr higher than prior quarter, causing ~14% sequential revenue shortfall. This accounting policy creates lumpy, unpredictable revenue.

Geopolitical situation from March 2026 drove significant raw material price increases across board. Q1 gross margin compressed 300 bps (56% → 53%). Management waiting for raw material stabilization before passing through price increases on CDMO contracts. No price increase clauses triggered in Q1. Rupee devaluation partially offsetting.

Vizag Phase 1 capex INR1,000 Cr over 3 years (INR250 Cr FY27 budgeted). Commercialization delayed to end FY29–FY30 (vs. prior market expectations of faster ramp). Asset turn normalization pushed to FY31–FY32. Significant execution and market-adoption risk.

4 chronic therapy programs tracked; 2 expected to fructify FY27–28. But 'initial quantities will not be significant because there will be small validation or clinical type of quantities.' 20 RFPs tracked, but only 4 with high conviction and clear timeline. Diversification thesis depends on successful commercialization 2+ years out.

Geopolitical situation (implied Russia-Ukraine/regional conflict) driving container shortage, shipping delays, and raw material price inflation. Transit delays reduced Q1 contrast media revenue by ~₹30 Cr. Supply chain normalization timeline unclear.